Gang Fang, PharmD, PhD
Dr. Fang’s overall research is centered in the areas of evaluating treatment utilization and outcomes in populations and pharmacoepidemiology especially in cardiovascular disease. His research primarily focuses on estimating real-world comparative treatment effectiveness and safety, identifying optimal treatment strategies, assessing treatment variation in large populations, assessing quality of care related to the treatment variation, and treatment disparities particularly in the elderly and minorities, and developing innovative analytical methods using observational data from large healthcare utilization databases.
Dr. Fang’s past research includes studies on treatment adherence, regimen modification and outcomes in elderly patients with diabetes and other chronic conditions. His current clinical research areas include acute myocardial infarction, hypertension, and diabetes. He is the principal investigator of an American Heart Association National Clinical Research Program Award. For the AHA study, he is investigating the comparative effectiveness of tissue vs. non tissue ACE inhibitors (a commonly used class of antihypertensive drugs) in secondary prevention post acute myocardial infarction. He was a key co-investigator for studies of total over $5 million funding from NIH, AHRQ, PCORI in evaluating comparative treatment effectiveness and advancing analytical methodology for CER.